A phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: A China single-center experience

Cancer Investigation

Volumn 25, Issue 7, 2007, Pages 599-605

  Xu, Nong ^a   Fang, Wei Jia ^a   Zhang, Xiao Chen ^a   Yu, Lan Fang ^a   Bao, Han Ying ^a   Shi, Gen Ming ^a   Huang, Sui ^a   Shen, Peng ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

5 fluorouracil infusion; Colorectal cancer; Leucovorin; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL PATIENT; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 36249000776     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701470739     Document Type: Article

References (20)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55 (2), 74-108.
2. Glimelius, B.; Hoffman, K.; Graf, W.; Pahlman, L.; Sjoden, P.O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994, 73 (3), 556-562.
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol. 1992, 10 (6), 896-903.
4. Poon, M.A.; O'Connell, M.J.; Moertel, C.G.; Wieand, H.S.; Cullinan, S.A.; et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989, 7 (10), n1407-1418.
5. De Gramont, A.; Bosset, J.F.; Milan, C.; Rougier, P.; Bouche, O.; et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997, 15 (2), 808-815.
6. Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997, 8 (9), 876-885.
7. De Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18 (16), 2938-2947.
8. Giacchetti, S.; Perpoint, B.; Zidani, R.; Le Bail, N.; Faggiuolo, R.; et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000, 18 (1), 136-147.
9. Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004, 22 (1), 23-30.
10. Levi, F.A.; Zidani, R.; Vannetzel, J.M.; Perpoint, B.; Focan, C.; et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst. 1994, 86 (21), 1608-1617.
11. De Gramont, A.; Vignoud, J.; Tournigand, C.; Louvet, C.; Andre, T.; et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997, 33 (2), 214-219.
12. Andre, T.; Louvet, C.; Raymond, E.; Tournigand, C.;de Gramont, A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 1998, 9 (11), 1251-1253.
13. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004, 350 (23), 2343-2351.
14. Tournigand, C.; Andre, T.; Achille, E.; Lledo, G.; Flesh, M.; et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22 (2), 229-237.
15. Maindrault-Goebel, F.; de Gramont, A.; Louvet, C.; Andre, T.; Carola, E.; et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol. 2000, 11 (11), 1477-1483.
16. Maindrault-Goebel, F.; Louvet, C.; Andre, T.; Carola, E.; Lotz, J.P.; et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur. J. Cancer 1999, 35 (9), 1338-1342.
17. Maindrault-Goebel, F.; de Gramont, A.; Louvet, C.; Andre, T.; Carola, E.; et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 2001, 37, (8),1000-1005.
18. Cheeseman, S.L.; Joel, S.P.; Chester, J.D.; Wilson, G.; Dent, J.T.; Richards, F.J.; Seymour, M.T. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br. J. Cancer 2002, 87, (4), 393-399.
19. De Gramont, A.; Cervantes, A.; Andre, T.; Fiiier, A.; Ledo, G.I.; et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. J. Clin. Oncol. 2004, 22 (Suppl. 14), 3525.
20. Grothey, A.; Sargent, D.; Goldberg, R.M.; Schmoll, H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004, 22 (7), 1209-1214.